Simeprevir (SMV) + Sofosbuvir (SOF) With or Without Ribavirin (RBV) for Interferon-intolerant or Ineligible (IFN-II) Patients With Chronic Hepatitis C (CHC)
Phase of Trial: Phase IV
Latest Information Update: 26 Jun 2018
Price : $35 *
At a glance
- Drugs Ribavirin (Primary) ; Simeprevir (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 05 Jul 2016 Status changed from active, no longer recruiting to completed.
- 30 Mar 2016 Planned End Date changed from 1 Dec 2016 to 1 Aug 2016 as reported by ClinicalTrials.gov.
- 25 Jan 2016 Planned end date changed from 1 Feb 2017 to 1 Dec 2016, as reported by ClinicalTrials.gov.